CSU secures $3.1 million from NIH to advance SolaVAX coronavirus vaccine research
Researchers at CSU have worked quickly and collaboratively to move this vaccine research forward.
Tag: "BioMARC"
CSU researchers part of national search for coronavirus vaccine
As the world looks for ways to stop the spread of the new coronavirus, Colorado State University has activated a unique combination of national experts, facilities, and vaccine manufacturing capability to help in the fight.
Why it's important to study neglected diseases: A conversation with BioMARC’s John Wyckoff
John Wyckoff talks about a new research project to develop a human vaccine against the Rift Valley Fever virus.
New director joins BioMARC
John Wyckoff will oversee operations relating to CSU’s research expertise in translational medicine in the Infectious Disease Research Center.
CSU works with CDC to help public health labs detect Zika virus
BioMARC, the university's vaccine manufacturing facility, created material to be used in labs nationwide in the fight against Zika virus.
BioMARC secures $3 million from the Department of Defense to advance vaccine development
CSU’s vaccine manufacturing facility, BioMARC, is developing a drug to protect U.S. soldiers from a mosquito-borne pathogen that can cause severe illness and death.
BioMARC helps advance vaccines for Department of Defense
Colorado State University’s Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) has been awarded a 10-month, $4.6 million contract funded by the Department of Defense (DoD) to help develop and manufacture new vaccines to fight encephalitic viruses that cause inflammation of the brain.
CSU to make Ebola, Marburg vaccines to support human trials
BioMARC, a high-containment biopharmaceutical facility operated by CSU, is manufacturing the vaccines for the U.S. Department of Defense in support of human clinical trials.